We share the latest works in TAVI published on our website.
Last Articles in TAVR in solaci.org
01- HYDRA CE | New Models for TAVR Development
The Hydra CE has shown favorable one year efficacy for the new transcatheter aortic valve model, with large effective orifice and low transvalvular gradient associated to an acceptable complications rate. With this study, the Hydra will obtain the CE mark and go after FDA approval (just as all new devices).
Read more HERE
02- TAVR vs Sutureless Surgical Aortic Valve Replacement in Low-Risk Patients
Sutureless surgical aortic valve replacement (SU-SAVR) has been designed to make surgical valve replacement easier and faster, especially compared against conventional biological valves which require multiple sutures; their rapid deployment translates into reduced cross-clamp and operative time.
Read more HERE
03- TCT 2021 | SURTAVI: Good News for the Self-Expandable Valve at 5 Years
After a 5-year followup, the transcatheter aortic replacement (TAVR) with the self-expandable valve has offered clinical outcomes similar to surgical aortic valve replacement (SAVR) outcomes for intermediate risk patients.
Read more HERE
04- Is Troponin Elevation After TAVR Related to Mortality?
Troponins have long had diagnostic value not only for infarction. Their ability to predict mortality is well established for all cardiac conditions. Moreover, it has been demonstrated in all critically ill patients, including patients with COVID-19, regardless of the triggering condition.
Read more HERE
05- Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines
The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines.
Read more HERE
06- European Consensus on Antithrombotic Management in TAVR
All the controlled randomized evidence recently published called for an updated document on antithrombotic management in transcatheter aortic valve replacement (TAVR).
Read more HERE
07- Minimizing One of Our Major Procedures to a Minimum
In some cases, full atrioventricular (AV) block occurs beyond two days after transcatheter aortic valve replacement (TAVR). This highlights the usefulness of extending monitoring after discharge, particularly in patients who tolerated the procedure well, but meet high-risk criteria.
Read more HERE
08- Ten Commandments for 2021 Guidelines on Valvular Heart Disease
Since the latest version to the Valvular Heart Disease Guidelines from the European Society of Cardiology, plenty of evidence has been accumulating, finally leading to this updated version.
Read more HERE
Subscribe to our weekly newsletter
Get the latest scientific articles on interventional cardiology
